A study to investigate how multiple oral doses of AZD2389 affect the pharmacokinetics of midazolam, caffeine, and bupropion in healthy participants - CRIOLLO

Exclusion Criteria

• - History of any clinically important disease or disorder which, in the opinion of the investigator, may either put the participant at risk.
• - History or presence of gastrointestinal, hepatic, or renal disease or any other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs.
• - Any clinically important illness, medical/surgical procedure, or trauma within 4 weeks of the first administration of study intervention.
• - Any clinically important abnormalities in clinical chemistry, coagulation, hematology, or urinalysis results.
• - Any positive result at the Screening Visit for serum hepatitis B surface antigen (HBsAg), hepatitis B core antibody (HBcAb), hepatitis C virus (HCV), or human immunodeficiency virus (HIV).
• - Abnormal vital signs, after 10 minutes supine rest, at the Screening Visit and/or admission to the Clinical Unit (Day -2).
• - Any clinically important abnormalities in rhythm, conduction, or morphology of the resting 12-lead safety ECG.
• - History of severe allergy/hypersensitivity or ongoing clinically important allergy/hypersensitivity.
• - History of hypersensitivity to DPP4 inhibitors, as judged by the investigator, or history of hypersensitivity to drugs with a similar chemical structure or class to DPP4 inhibitors.
• - History of severe dermatological disorders, eg, bullous pemphigoid or Stevens-Johnson syndrome, as judged by the investigator.
• - Participants who have previously received AZD2389 within the last 12 months prior to the Screening Visit.
• - Known hypersensitivity or previous adverse events associated with midazolam, caffeine, or bupropion.